These results suggest the potential use of recombinant TRAIL as a novel therapeutic agent; they also suggest the possible contribution of endogenously expressed TRAIL in immunotherapy against BCR-ABL1-positive leukemia. This evidence concerns the gene TNFSF10 and leukemia.